Key facts
- It has raised $9.7M across 1 recorded rounds; the latest was Early Stage VC ($9.7M) in Mar 2026.
- Notable investors include Even One Ventures.
- Valius Health has filed 1 Form D with the SEC, most recently Apr 2026 ($9.7M sold to 6 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Valius Health
Funding rounds
1 roundsAbout Valius Health
Developer of precision oncology diagnostics designed to generate comprehensive molecular profiles for personalized cancer treatment planning. The company provides multi-omic testing across DNA, RNA and protein layers, integrates bioinformatic comparison against large tumor datasets and provides accessible, shareable data for clinicians and patients, enabling patients with aggressive cancers to prioritize therapies based on each tumor's specific molecular characteristics.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 6
- Website
- valiussciences.com/
- Ownership
- Privately Held (backing)
Valius Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Valius Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Valius Health in its N-PORT filings yet. We sweep new filings monthly.